Clinical Trials Browser

Completed × Carcinoma, Transitional Cell × 90 days × Clear all

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT05226117 2026-03-27

Sacituzumab Govitecan, Preceding Radical Cystectomy, in Treating Patients With Muscle-invasive Bladder Cancer

Phase 2 Completed

44 enrolled

Genitourinary

Carcinoma, Transitional Cell

NCT06894771 2026-03-16

MK-4700-001

Phase 1 Completed

5 enrolled

BreastDermatologicGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Melanoma, Neoplasms, Triple Negative Breast Neoplasms

NCT01616875 2026-03-06

Bristol Bladder Trial

Phase 2 Completed

28 enrolled 21 charts

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT03898180 2026-02-05

LEAP-011

Phase 3 Completed

505 enrolled 19 charts

Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Transitional Cell

NCT02989064 2026-02-04

MAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck Cancers

Phase 1 Completed

10 enrolled

DermatologicGenitourinaryHead & Neck

Carcinoma, Transitional Cell, Head and Neck Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms

Clinical Trials

AVENANCE

Sacituzumab Govitecan, Preceding Radical Cystectomy, in Treating Patients With Muscle-invasive Bladder Cancer

MK-4700-001

Bristol Bladder Trial

LEAP-011

MAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck Cancers